Spero Therapeutics (SPRO) Equity Ratio (2016 - 2026)

Spero Therapeutics (SPRO) has 11 years of Equity Ratio data on file, last reported at 0.9 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 106.11% year-over-year to 0.9; the trailing twelve-month figure through Mar 2026 stood at 0.9 (up 106.11% YoY), and the FY2025 full-year result was 0.86, up 105.25% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.9, up from 0.86 in the prior quarter.
• Across five years, Equity Ratio topped out at 0.9 in Q1 2026 and bottomed at 0.42 in Q4 2024.
• The 5-year median for Equity Ratio is 0.54 (2024), against an average of 0.56.
• The widest annual swing landed in 2022, when Equity Ratio plunged 48.3%; it then jumped 106.11% in 2026.
• A 5-year view of Equity Ratio shows it stood at 0.61 in 2022, then dropped by 3.68% to 0.59 in 2023, then dropped by 28.81% to 0.42 in 2024, then surged by 105.25% to 0.86 in 2025, then rose by 4.73% to 0.9 in 2026.
• The last three Equity Ratio figures came in at 0.9 (Q1 2026), 0.86 (Q4 2025), and 0.49 (Q3 2025), per Business Quant data.

Peer Comparison